Skip to main content

Nephron Announces FDA Approval of Ketorolac, Signaling New Phase of Growth

WEST COLUMBIA, S.C. – Nephron Pharmaceuticals Corporation is celebrating another milestone.

The company today announced Food and Drug Administration (FDA) approval of the Nephron Abbreviated New Drug Application (ANDA) for Ketorolac Tromethamine Injection USP, 60 mg/2 mL (30 mg/mL) in Single-Dose Vials. The vials are made of polypropylene plastic with a “luer lock” interface for needle-free dosing and are manufactured using Blow-Fill-Seal (BFS) technology.

Ketorolac Tromethamine becomes one of the first ANDA-approved non-respiratory generic medications produced by Nephron, signaling a new phase of company growth. Nephron secured FDA approval for Sodium Chloride IV Bags earlier this year.

“We are extraordinarily excited to expand our generic medication portfolio to include non-respiratory products,” said Nephron CEO Lou Kennedy. “This is the latest sign that Nephron is growing, and it represents a real reason for our entire team to celebrate.”

Nephron-manufactured Ketorolac Tromethamine is an injectable medication for the short-term treatment (up to 5 days) of moderately severe acute pain. Commonly used after surgeries and other medical procedures, Ketorolac Tromethamine is a nonsteroidal anti-inflammatory drug (NSAID).

A West Columbia, S.C.-based company, Nephron develops and produces safe, affordable generic inhalation solutions and suspension products.

The company also operates an industry-leading 503B Outsourcing Facility division which produces pre-filled sterile syringes and IV bags for hospitals across America, in an effort to alleviate their drug shortage needs. The company recently opened a CLIA-certified diagnostics lab and conducts COVID-19 tests for people across South Carolina.

Prescribing information for Ketorolac Tromethamine Injection Vial UPS, 60 mg/2 mL (30 mg/mL) is available on the product Package Insert. More product information regarding Ketorolac Tromethamine Injection USP, 60 mg/2 mL (30 mg/mL) in Single-Dose Vials is available here.

Nephron Pharmaceuticals Continues to Support Lexington One Pharmacology Students

LEXINGTON, S.C. — Nephron Pharmaceuticals Corporation and CEO Lou Kennedy continue to provide generous financial support to Lexington School District One students via donations to the Lexington One Educational Foundation.

Kennedy recently gave a $7,500 check to the Educational Foundation, which will cover the course fees for students enrolled in Lexington District One’s Pharmacology class. The district will offer the course at the Lexington Technology Center and Pelion High School during the second semester of the 2020-21 school year.

This donation is significant, since the Pharmacology course fees are $300 per student. The gift enables students who may be interested in a pharmacy career to take the class with no concern for the excessive fee.

This year 25 students are enrolled in the class between the two district locations.

“We could not be more excited to partner once again with Lexington One,” said Kennedy. “These students deserve to be equipped with the very best educational resources available because they represent South Carolina’s – and our company’s – future workforce.”

This is the fourth year that Nephron Pharmaceuticals has supported this program in an effort to open the class to all students in Lexington District One, regardless of the cost. In recent years, the company has also donated a Laminar Flow Hood, Refiller equipment, syringes, vials and protective suits for the students to use while learning about the pharmacy industry. Nephron staff have also visited the class in past years (prior to COVID-19) and shared their industry knowledge with the pharmacology students.

Foundation Executive Director Julie Anderson Washburn stated on behalf of the Foundation, “We are extremely thankful to Lou Kennedy and Nephron Pharmaceuticals for the company’s continued investment in our Lexington One students through their donation. Thanks to this charitable gift, any of our seniors who are interested in the Pharmacology course are able to pursue it and explore a possible future career goal.”

-###-
 

Contact Us